Understanding Heart Risks After Lymphoma Treatment: What Patients Need to Know About Chemotherapy and Radiation Side Effects

Table of Contents

• Key Points
• Why This Research Matters
• How the Researchers Conducted This Study
• Key Findings: The Numbers Explained
• How Common Are Heart Problems 25 Years Later?
• Combined Risk: When Chemotherapy and Radiation Are Used Together
• What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In over 22,000 lymphoma patients, both anthracycline chemotherapy and chest radiation cause dose-dependent heart damage, with no safe lower dose.
• For heart failure, anthracyclines dominate: risk rises 92% per 100 mg/m²; radiation adds 6.1% per Gray.
• For blocked coronary arteries, radiation is the main driver, increasing risk 4.4% per Gray; anthracyclines showed no effect.
• Heart valve damage rises with both treatments: 25% per 100 mg/m² anthracyclines and 10% per Gray radiation.
• Heart problems typically appear 15–25 years after treatment; follow-up, symptom awareness, not smoking, and controlling cardiac risk factors are important.

Why This Research Matters

Lymphoma is a type of cancer that affects the lymphatic system, which is part of the body's immune system. Fortunately, most lymphomas can be treated very effectively, and many patients are cured. But the very treatments that save lives — chemotherapy and radiation therapy — can sometimes cause serious health problems years later. One of the most concerning long-term side effects is damage to the heart.

Two types of treatment are known to affect the heart:

• Anthracyclines — a family of powerful chemotherapy drugs (including doxorubicin, also known as Adriamycin) that are standard treatments for many lymphomas. These drugs accumulate in heart muscle cells, injure the inner lining of blood vessels, and cause heart muscle cells to die. Over time, this can thin the walls of the heart's pumping chambers and weaken the heart's ability to pump blood effectively.
• Radiation therapy to the chest — radiation aimed at lymphoma in the chest area can damage all the structures of the heart, including the coronary arteries (the blood vessels that supply the heart), the heart valves, and the heart muscle itself.

Previous research has shown that radiation to the heart after breast cancer treatment increases the risk of heart attacks by 7.4% per 1 Gray (Gy) of mean heart dose, with no safe threshold. A Gray is the unit used to measure the amount of radiation energy absorbed by tissue. Similar findings have been reported in lymphoma survivors.

Modern radiation techniques — called Involved Site Radiation Therapy (ISRT) — are much more precise than older methods. They use PET/CT scans to define the exact target, breathing management to reduce heart exposure, and daily imaging to ensure accuracy. These advances have dramatically reduced radiation doses to the heart. However, even with modern techniques, the radiation oncologist must be able to choose the right approach for each individual patient, which means they need accurate information about how much risk each treatment carries.

Much of the data we have on heart toxicity comes from patients treated decades ago, when larger radiation fields were used. Those patients' experiences can't directly tell us the risk for patients treated today. But they can teach us something very valuable: the dose-response relationship — that is, the mathematical relationship between how much treatment a patient received and how likely they are to develop heart problems. This information can then be used to estimate risks for patients being treated with modern, more targeted approaches.

How the Researchers Conducted This Study

The researchers performed a systematic review of the medical literature, following strict international guidelines called the PRISMA guidelines. This approach ensures that the review is thorough and that no important studies are missed.

The literature search. The team searched PubMed (the largest medical research database) using search terms including "Radiotherapy AND Cardiovascular AND lymphoma" and "Radiotherapy AND cardiotoxicity AND lymphoma." They looked for English-language publications from January 2000 through December 2022 that included:

• Data on patients treated for lymphoma or blood cancers
• Estimates of radiation dose to the heart
• Information about anthracycline chemotherapy doses
• Long-term cardiac (heart) outcomes

Studies without dose-response information were excluded. The search was completed in June 2023 and updated after the publication of a major international report called PENTEC (Pediatric Normal Tissue Effects in the Clinic). In total, 15 potential studies were assessed in detail, but only 6 papers met all the criteria for inclusion. Studies were excluded for reasons such as having overlapping patient populations or lacking the specific dose information needed.

Which heart problems were studied? The researchers focused on three specific types of heart damage:

1. Congestive heart failure (CHF) — a condition where the heart can't pump blood as well as it should, causing symptoms like shortness of breath, fatigue, and swelling in the legs
2. Ischemic heart disease (IHD) — reduced blood flow to the heart muscle, usually due to narrowing of the coronary arteries, which can cause chest pain (angina) or heart attacks
3. Valvular heart disease (VHD) — damage to the heart's valves, which control the direction of blood flow through the heart

Measuring dose. For radiation, the researchers used the "mean heart dose" (MHD) — the average radiation dose received by the whole heart — because this was the most consistently reported measurement across studies. For anthracyclines, doses were recorded in milligrams per square meter of body surface area (mg/m²), which is the standard way chemotherapy doses are measured.

Combining the data. Different studies reported their results in different ways. Some used odds ratios, some used hazard ratios, and others used relative risks. The researchers converted all these different types of measurements into a single standard measure called the Excess Relative Risk (ERR) — which describes how much the risk of a heart problem increases (in percentage terms) for each additional unit of treatment. For example, an ERR of 92% per 100 mg/m² means that for every additional 100 mg/m² of anthracycline given, the risk of heart failure increases by 92% compared to someone who received no anthracyclines.

To convert between different types of risk measurements, the researchers needed a "background incidence" — the rate at which these heart conditions normally occur in the general population. They used data from the Danish Heart Foundation for people aged 55–64 years (0.5% for congestive heart failure, 0.8% for ischemic heart disease, and 0.4% for valvular heart disease). They ran sensitivity analyses to confirm that this specific choice didn't meaningfully affect the results.

The statistical model. The researchers combined data using linear regression with zero intercept — meaning they assumed the risk starts at zero when the dose is zero and increases in a straight line as the dose increases. Each data point was weighted by inverse variance, which gives more influence to more precise studies. The regression coefficient is reported with 95% confidence intervals (CI) — the range within which the true value is likely to fall with 95% certainty. Heterogeneity (variability between studies) was assessed visually from dose-response plots.

Key Findings: The Numbers Explained

Six studies involving a total of 22,916 patients were included in the final analysis. Here's what the dose-response data showed for each type of heart problem.

Congestive Heart Failure (CHF) — The Biggest Concern

Both treatments contribute to heart failure risk, but anthracycline chemotherapy is the dominant factor.

• Anthracyclines: The excess relative risk of CHF increases by 92% per 100 mg/m² of anthracyclines (95% CI: 74%–101%). To put this in perspective, 100 mg/m² is the dose given in 2 cycles of common lymphoma chemotherapy regimens called ABVD or CHOP.
• Radiation therapy: The excess relative risk of CHF increases by 6.1% per Gray (Gy) of mean heart dose (95% CI: 4.4%–7.6%).

This means that a patient receiving 400 mg/m² of anthracyclines (8 cycles of ABVD or CHOP) would have roughly a 350% increase in risk of heart failure — in other words, their risk would be about 4.5 times higher than someone who received no anthracyclines.

Ischemic Heart Disease (IHD) — Radiation Is the Main Culprit

The findings for blocked coronary arteries were very different:

• Anthracyclines: No effect was found of anthracycline dose on the risk of ischemic heart disease.
• Radiation therapy: The excess relative risk of IHD increases by 4.4% per Gy of mean heart dose (95% CI: 2.7%–6.1%). This agrees with earlier individual studies, including a landmark paper by van Nimwegen and a major study by Darby on breast cancer patients.

This makes biological sense: radiation damages the blood vessel walls, accelerating the buildup of plaque that narrows the coronary arteries. Chemotherapy, by contrast, primarily affects the heart muscle cells themselves.

Valvular Heart Disease (VHD) — Both Treatments Contribute

Heart valve damage showed a mixed picture, with both treatments playing a role:

• Anthracyclines: The excess relative risk of VHD increases by 25% per 100 mg/m² of anthracyclines (95% CI: 13%–37%).
• Radiation therapy: The excess relative risk of VHD increases by 10% per Gy of mean heart dose (95% CI: 6%–13%).

Does a "Safe" Dose Exist?

The most important finding from the analysis is that the data are consistent with a linear no-threshold dose-response relationship for all three heart conditions. This means:

• There is no dose of radiation or anthracyclines below which the risk is zero
• Risk increases in a straight line with increasing dose
• Even low doses carry some small level of risk

This finding challenges older assumptions that a threshold dose of 300 mg/m² of doxorubicin (a common anthracycline) was safe. Modern studies clearly show no safe lower dose and an approximately linear dose-response relationship, which is exactly what this analysis confirmed.

How Common Are Heart Problems 25 Years Later?

The researchers also collected data on cumulative incidence — the percentage of patients who develop a heart condition within 25 years of their lymphoma treatment. These data came from five large studies.

For adult lymphoma survivors:

• Valvular heart disease: 8% to 19% of patients developed valve problems within 25 years
• Ischemic heart disease: 6% to 14% of patients developed blocked coronary arteries
• Congestive heart failure: 5% to 7% of patients developed heart failure

Time to heart problems. Heart problems typically take years to develop after cancer treatment. The median time from treatment to diagnosis was approximately:

• Congestive heart failure: about 18 years (range 15.8–19.5 years)
• Ischemic heart disease: between 15.8 and 19.5 years
• Valvular heart disease: between 16.1 and 24 years

This long time lag explains why it took decades for researchers to fully understand these risks, and why long-term follow-up of lymphoma survivors is so important.

Combined Risk: When Chemotherapy and Radiation Are Used Together

Many lymphoma patients receive both anthracycline chemotherapy and radiation therapy. The researchers combined their dose-response models for both treatments to create a joint estimate of risk. Figure 4 in the original paper provides radiation dose-response estimates at five representative anthracycline dose levels: 0, 100, 200, 300, and 400 mg/m².

To help patients understand these numbers:

• 100 mg/m² = 2 cycles of ABVD or CHOP chemotherapy
• 200 mg/m² = 4 cycles of ABVD or CHOP
• 300 mg/m² = 6 cycles of ABVD or CHOP
• 400 mg/m² = 8 cycles of ABVD or CHOP

Here's a practical example from the research: a cumulative dose of 400 mg/m² of anthracyclines produces an excess relative risk for heart failure of about 350%. If that same patient also receives 5 Gy of mean heart dose from radiation, the risk increases to approximately 400%. And a dose of 200 mg/m² of anthracyclines (4 cycles of ABVD) carries roughly the same heart failure risk as 28 Gy of mean heart dose from radiation alone.

In summary:

• Congestive heart failure: Anthracycline dose is the dominant risk factor
• Ischemic heart disease: Radiation is the dominant — and effectively the only — risk factor
• Valvular heart disease: Both treatments contribute, with radiation having a slightly stronger per-unit effect

What This Means for Patients

These findings have important implications for how lymphoma is treated.

Personalized treatment decisions. For most types of lymphoma, both radiation therapy and systemic treatments (chemotherapy) are effective options. Finding the optimal combination for each individual patient — achieving the highest chance of cure while minimizing serious long-term side effects — has always been a challenge. Until now, treatment decisions have been made in a largely qualitative way, considering only a few side effects one by one, using simple rules like "keep the mean heart dose below a certain number."

This new research provides the quantitative tools needed for a more sophisticated, individualized approach. For the first time, doctors can calculate a combined risk estimate for all three major cardiac endpoints based on the cumulative doses of both anthracyclines and radiation to the heart for each specific patient.

Modern radiation is safer, but not risk-free. Most patients treated with current advanced radiation techniques receive a mean heart dose that is typically below 5 Gy. The risk of cardiotoxicity from radiation at these low doses is relatively small. However, the risk can still be significant in some patients, depending on the location of the lymphoma in the chest. This highlights the need for a personalized approach to assess radiation-related risk.

No safe anthracycline dose. A common practice has been to limit the maximum cumulative anthracycline dose to 450 mg/m², based on the assumption that this dose level corresponds to about a 5% incidence of symptomatic heart failure. This study's data suggest that a 400 mg/m² cumulative dose of anthracyclines is associated with a threefold excess relative risk of heart failure. Importantly, some patients develop severe heart failure at much lower doses, and no safe dose exists. Individual tolerance appears to depend significantly on patient-related risk factors — especially age.

Smoking amplifies the risk. The researchers note that van Nimwegen found that the population was at risk of more than one cardiac event, and the risk was further increased among patients who smoked. This is a critical, modifiable risk factor for lymphoma survivors.

Study Limitations

It's important to understand what this study could and couldn't prove. The researchers were transparent about several limitations:

• Old treatment techniques. Most of the data come from patients treated in the era of two-dimensional radiation planning, when larger treatment volumes were used. The dose estimates are therefore not directly equivalent to the more precise doses delivered with modern techniques.
• Estimated doses, not measured doses. Radiation doses were estimated from medical records and published studies, not from individual patient treatment plans. Some variability in dose estimation should be acknowledged.
• Mean heart dose is a simplification. The mean heart dose (MHD) doesn't capture how radiation is distributed within the heart. Modern techniques can deliver quite different doses to different parts of the heart (valves, coronary arteries, conduction system) while having the same mean dose. Radiation to different substructures may carry different risks for different types of heart disease. One study (Cutter et al.) used a more refined dose metric for valvular dose and could not be reconciled with the linear model — those data were excluded from the analysis.
• Risk of overestimating MHD. The PENTEC reports found that prescribed mean heart dose may be overestimated by 30%, which would lead to underestimating the actual risk.
• Binned dose data. Anthracycline doses were reported in ranges or "bins" rather than as exact individual doses. The analysis used the midpoint of each bin.
• First events only. The excess relative risk estimates in this study are for the first cardiac event. Many patients may experience more than one type of cardiac problem or have recurrent events.
• Pediatric cohort inclusion. Some of the included studies focused on childhood cancer survivors, whose risk profiles may differ from adult lymphoma patients.
• Patient-reported outcomes. In one study, the cumulative incidence of heart problems was based on patient self-reports rather than medical records.

Despite these limitations, the researchers note that the consistency of the dose-response relationships across the included studies (visible in the plotted figures) makes it unlikely that the linear dose-response relationship does not hold.

Recommendations for Patients

Based on this research, here are key takeaways for lymphoma patients and survivors:

Before Treatment: Ask Your Doctor About Heart Risks

1. Ask about your cumulative anthracycline dose. Every dose adds up. Ask your oncologist what your total planned dose will be (in mg/m²) and how that translates into heart failure risk based on the data from this study (92% increase in excess relative risk per 100 mg/m²).
2. Ask about your predicted mean heart dose from radiation. If you need radiation to the chest, ask what your expected mean heart dose will be in Gy. Modern techniques should keep this below 5 Gy in most cases. The research shows a 6.1% increase in heart failure risk per Gy of mean heart dose.
3. Discuss the combined risk. If you're receiving both treatments, the risks add together. Your doctors can now use combined estimates like the ones in this study to understand your total predicted cardiac risk.
4. Ask about alternative regimens. For some lymphoma types, there may be treatment options that reduce heart exposure. This doesn't mean compromising on cure — it means choosing the approach that gives you the best balance of cancer control and long-term health.

After Treatment: Monitor Your Heart Health

1. Keep regular follow-up appointments. Heart problems can develop 15–25 years after treatment. Long-term follow-up with a cardiologist or your oncology team is essential.
2. Watch for symptoms. Be alert to shortness of breath, chest pain, palpitations, unusual fatigue, or swelling in your legs or feet — and report them to your doctor promptly.
3. Consider cardiac screening. Ask your doctor whether you should have an echocardiogram (an ultrasound of the heart) or other cardiac tests to check your heart function, even if you feel well.
4. Don't smoke. Smoking significantly amplifies the risk of heart problems after lymphoma treatment. If you smoke, talk to your doctor about smoking cessation programs.
5. Manage other risk factors. Keep blood pressure, cholesterol, and blood sugar in healthy ranges. These standard cardiac risk factors add to the risk from cancer treatment.
6. Remember: no dose is "safe." Even if you received low doses of anthracyclines or radiation, you still have some increased risk. That doesn't mean you will develop heart problems — it means you and your doctors should be aware and proactive.

For Future Patients: This Research Will Improve Treatment Planning

The researchers are working toward creating quantitative tools that combine data on multiple long-term toxicities (not just cardiac effects) with patient risk factors. This will allow doctors to optimize treatment for each individual patient, balancing cure rates against all the potential long-term side effects. The authors note that machine learning is now being developed to automate contouring (delineation) of the heart and its substructures on treatment plans, which will allow future studies to look at more detailed dose information than just mean heart dose.

Frequently Asked Questions

What heart problems can develop years after lymphoma treatment?

The three main types are congestive heart failure, where the heart cannot pump well; ischemic heart disease, caused by narrowed coronary arteries; and valvular heart disease, which damages heart valves. Both anthracycline chemotherapy and radiation to the chest contribute, but in different ways and after many years.

Is there a safe low dose of anthracycline chemotherapy or chest radiation?

No safe dose exists. The analysis found a linear no-threshold relationship for all three heart conditions, meaning even low doses carry some risk and risk increases steadily with dose. This challenges older assumptions that a certain threshold, like 300 mg/m² of doxorubicin, was safe.

How much does anthracycline chemotherapy increase the risk of heart failure?

In this analysis of over 22,000 lymphoma patients, the excess relative risk of congestive heart failure rises by 92% for every additional 100 mg/m² of anthracyclines, which is the dose in two cycles of common regimens like ABVD or CHOP. Eight cycles would roughly quadruple the risk.

Which treatment is mainly responsible for blocked coronary arteries after lymphoma?

Radiation therapy to the chest is the dominant and effectively the only risk factor for ischemic heart disease in this analysis. Anthracycline dose showed no effect on this condition. The excess relative risk increases by 4.4% per Gray of mean heart dose.

How long after treatment can heart problems appear?

Heart problems typically take many years to develop. In the included studies, the median time from treatment to diagnosis was about 18 years for congestive heart failure, 15.8 to 19.5 years for ischemic heart disease, and 16.1 to 24 years for valvular disease. Long-term follow-up is essential.

What should I ask my doctor before starting lymphoma treatment?

Ask about your planned cumulative anthracycline dose in mg/m² and your expected mean heart dose from radiation in Gray, especially if radiation targets the chest. Ask how these combine to estimate your total heart risk, and whether alternative regimens could reduce heart exposure without compromising cure.

What can lymphoma survivors do to protect their heart health?

Keep regular follow-up appointments because heart issues can appear 15 to 25 years later. Watch for shortness of breath, chest pain, palpitations, fatigue, or leg swelling. Ask about cardiac screening such as an echocardiogram. Do not smoke, because smoking amplifies the risk, and manage blood pressure, cholesterol, and blood sugar.

My lymphoma treatment plan includes chemotherapy and chest radiation. Should I get a second opinion to check my risk of heart damage?

Yes. Both anthracycline chemotherapy and radiation to the heart raise the risk of heart failure, blocked coronary arteries, and valve damage, and that risk increases linearly with no safe lower dose. Heart problems may not appear for 15–25 years. A second opinion can let another oncology team review your planned cumulative anthracycline dose in mg/m² and your predicted mean heart dose in Gy, and clarify whether alternative regimens or modern radiation techniques could reduce that combined cardiac risk while still treating the lymphoma effectively. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response.

Authors: Nygård L, Vogelius IR, Kofoed KF, Bentzen S, Specht L.

Journal: Hematological Oncology, 2025; Volume 43, Article e70134

Affiliations: Department of Oncology, Section of Radiotherapy, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Institute of Clinical Medicine, University of Copenhagen; Department of Cardiology, Copenhagen University Hospital – Rigshospitalet; Department of Epidemiology and Public Health, School of Medicine, University of Maryland, Baltimore, Maryland, USA

Publication dates: Received March 20, 2025; Revised August 4, 2025; Accepted August 18, 2025

Funding: The authors received no specific funding for this work.

Keywords: anthracyclines; dose-response; late cardiac toxicity; lymphoma; radiotherapy

This patient-friendly article is based on peer-reviewed research published in an open-access format under the Creative Commons Attribution-NonCommercial License. The original article is by Nygård et al., published by John Wiley & Sons Ltd. This translation is provided for educational purposes and does not constitute medical advice. Patients should discuss their individual treatment-related cardiac risks with their oncology and cardiology care teams.